Universitaetsmedizin Goettingen — Sponsor Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

5 Recruiting

3 Completed trials

5 Countries active

13 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase I (FiH)

Phase III: 2 Phase II: 5 Phase IV: 1 Phase I (FiH): 1

Oversight events:

1 urgent safety measure across 1 trial

View oversight register →

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Alport's syndrome 1 Kearns-Sayre syndrome 1 Binge eating 1 Aortic stenosis 1

Top IMPs

ALLOGENEIC INDUCED PLURIPOTENT STEM CELLS-DERIVED CARDIOMYOCYTES AND STROMAL CELLS 1 CABOZANTINIB 1 DAPAGLIFLOZIN 1 FERRIC DERISOMALTOSE 1 FLUOROURACIL 1 FOLINIC ACID 1 HYDROCORTISONE 1 IRINOTECAN HYDROCHLORIDE TRIHYDRATE 1 OXALIPLATIN 1 PLACEBO 1 SODIUM CHLORIDE 1 SPIRONOLACTONE 1

All trials

9 total

Cognitive Function, Depression, Anxiety, and Quality of Life in Chronic Heart Failure Patients with Iron Deficiency with and without Anaemia… Pending

2024-515046-17-00 Phase IV 1 country FERRIC DERISOMALTOSE; SODIUM CHLORIDE
Folinic acid therapy in patients with Kearns-Sayre syndrome (KSS) and cerebral folate deficiency - mitoFolat Recruiting

2023-503730-45-00 Phase II 1 country
Dapagliflozin in patients with Right Heart Failure (Dapa-RHF) Recruiting

2024-515044-23-01 Phase II 1 country
DOUBLE PRO-TECT Alport: A confirmatory, multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the effect of Dap… Recruiting

2023-508502-18-00 Phase III 1 country DAPAGLIFLOZIN; PLACEBO
Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone:… Recruiting

2023-503558-10-00 Phase III 4 countries FLUOROURACIL; FOLINIC ACID; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; OXALIPLATIN
Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal… Recruiting

2024-515708-38-01 Phase I (FiH) 1 country ALLOGENEIC INDUCED PLURIPOTENT STEM CELLS-DERIVED CARDIOMYOCYTES AND STROMAL CEL…
CABONEN – a phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3 Ended

2024-510863-50-00 Phase II 2 countries CABOZANTINIB
Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder Ended

2024-515475-35-00 Phase II 1 country HYDROCORTISONE
Effect of antifibrotic therapy on regression of myocardial fibrosis after transcatheter aortic valve implantation (TAVI) in aortic stenosis … Ended

2024-510869-42-00 Phase II 1 country SPIRONOLACTONE

Showing 1–9 of 9 trials

← All sponsors A–Z